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ABSTRACT
Introduction:Chronic, nonspecif ic low back 
pain is a diff icult ailment to treat and poses 
an economic burden in terms of medical 
expenses and productivity loss. The aim of 
this study was to determine the eff icacy and 
safety of intramuscular metylcobalamin in 
the treatment of chronic nonspecific low back 
pain.
Methods :  This  was a double -b l inded , 
randomised, controlled experimental study. 
60 patients were assigned to either the 
methylcobalamin group or the placebo group. 
The former received intramuscular injections 
of 500 mcg parenteral methylcobalamin in 1 
ml solution three times a week for two weeks, 
and the placebo group received 1 ml normal 
saline. Patients were assessed with Oswestry 
Disability Index questionnaire Version 2.0 and 
Visual Analogue Scale pain score. They were 
scored before commencement of the injections 
and at two months interval.
Results : Of the 60 patients, 27 received 
the placebo injections and 33 were given 
methylcobalamin injections. A total of 58 
patients were available for review at two 
months (placebo: n is 26; methylcobalamin: n is 
32). There was a significant improvement in the 
Oswestry Disability Index and Visual Analogue 
Scale pain scores in the methylcobalamin 
group as compared with the placebo group 
(p-value less than 0.05) . Only minor adverse 
reactions such as pain and haematoma at the 
injection sites were reported by some patients.
 
Conclusion: Intramuscular methylcobalamin is 
both an effective and safe method of treatment 
for patients with nonspecif ic low back pain, 
both singly or in combination with other forms 
of treatment.
Keywords: methylcobalamin, nonspecif ic low 
back pain, vitamin B
12
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INTRODUCTION
Low back pain (LBP) affects a substantial proportion of 
the population. Almost every person will encounter an 
episode of back pain at some point in one’s life. Back 
pain does not discriminate based on gender, age, race or 
culture. It disables the working adult from performing his 
duties and paralyses the society due to the cost incurred 
in terms of treatment and productivity loss. In 1988, a 
survey was conducted in a semirural area in Malaysia. 
A total of 2,594 individuals from a multi-racial (Malay, 
Chinese, Indian) community were interviewed. The 
Community Orientated Programme for the Control of 
Rheumatic Diseases protocol was utilised. The survey 
reported that up to 11.6% of the population were affected 
by LBP.(1)
 Nonspecific low back pain (NSLBP) refers to pain 
that cannot be fully explained and has no apparent physical 
cause. There is no causal link between any specific 
physical diagnosis and the pain. NSLBP can be defined 
by symptoms occurring primarily in the back, which 
suggests neither nerve root compression nor a serious 
underlying condition. There is no verifiable physical 
pathology, anatomic lesion or deformity identified that 
can link to the patient’s symptoms. NSLBP encompasses 
common diagnoses such as lumbago, myofascial 
syndromes, muscle spasms, mechanical LBP, back sprain 
and strain. Patients with these vague conditions have 
pain in the lumbar region that may radiate to one or both 
thighs. The published literature reports that up to 85% of 
patients aged 25–55 years with back pain were diagnosed 
with NSLBP.(2,3)
 The use of vitamin B12 in the treatment of LBP has been 
established. In animal studies, vitamin B12 has been shown 
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to reduce pain in the test subjects.(4-9) Its synergistic effect 
with  non-steroidal anti-inflammatory drugs (NSAIDs) 
has also been proven in laboratory animal tests.(10-13) 
In clinical setting, vitamin B12 was found to reduce NSAID 
dosage and its duration in patients with back pain.(14-16) 
Methylcobalamin, an active analogue of vitamin B12, 
has been shown to improve neuropathic pain(17-19) 
and neurologic claudication distance in patients with 
lumbar spinal stenosis.(20) Some postulate that vitamin 
B12 has analgesic properties or analgesia-enhancing 
actions that increase the availability and effectiveness 
of noradrenaline and 5-hydroxytryptamine, acting as 
inhibitory transmitters in the nociceptive system.(21) 
However, these properties were only noted when high 
concentrations of the vitamin were administered. There 
were others who claimed that no strong evidence exists to 
prove that B vitamins have any analgesic properties.(22-24) 
Intramuscular administration of vitamin B12 is known 
to produce rapid and higher serum levels.(25,26) It is 
hypothesised that a higher level of serum vitamin B12 
is needed to ensure the exhibition of the nociceptive 
therapeutic action.
 To date, only one prospective study in Europe had 
looked into the effectiveness of intramuscular vitamin 
B12 in alleviating LBP and its related disability. In this 
double-blinded, randomised clinical trial, intramuscular 
Tricortin 1000 (1000 μg Vitamin B12 in 2-ml ampoules) 
was used, and the authors concluded that parenteral 
vitamin B12 is efficacious and safe in treating patients with 
LBP.(27) The current study was conducted to determine the 
actual role of vitamin B12 in the management of chronic 
NSLBP.
METHODS
This was a double-blinded, randomised controlled 
experimental study in which randomisation was done 
with a computerised software. The study was approved 
by the medical ethics board and registered under 
the Malaysian Science and Technology Information 
Centre. Patients of both genders, aged 20–65 years with 
symptoms of NSLBP lasting more than six months and 
who fulfilled the inclusion and exclusion criteria, were 
randomly assigned to one of the two study groups. The 
treatment group received methylcobal containing 500 
μg of parenteral methylcobalamin in 1-ml ampoules, 
and the placebo group received normal saline. The study 
was conducted at the Orthopaedic Specialist Clinic of 
Hospital Tuanku Jaafar, Malaysia from August 2006 
to April 2007. The sample size was determined based 
on an estimation to achieve a study power of 80% and 
a 5% level of significance. The two main research 
instruments used were the Oswestry Disability Index 
(ODI) questionnaire Version 2.0 and Visual Analogue 
Scale (VAS) pain score.
 Before the initiation of treatment, the patients were 
instructed to complete the ODI questionnaires and to 
chart their VAS pain scores. A total of six intramuscular 
injections of methylcobal were administered to the 
patients in two weeks (three intramuscular injections 
were given on Days 1, 3 and 5 each week). This regime 
was the recommended dosage for peripheral neuropathy. 
All patients were also prescribed tablet paracetamol and 
advised to consume when needed, with a maximal dose 
of 3 g per day. The patients were followed up for two 
months after the initiation of treatment, and the ODI 
questionnaires and VAS pain scores were taken at the 
end of the period.
 Pregnant women, patients on drugs known to have 
toxic effects on peripheral nerves, those with severe 
concurrent illnesses (e.g. uncontrolled diabetes mellitus 
or hypertension, ischaemic heart disease, end-stage renal 
failure, cerebral vascular disease or malignant cancers), 
known B12 allergy, megaloblastic anaemia, symptoms 
suggestive of specific LBP (including symptoms that can 
be attributed to a systemic disease, infection, tumour, 
injury, trauma or structural deformity) and patients 
who wished to continue with other forms of treatment 
(e.g NSAIDs, physiotherapy or exercise programmes) 
were excluded from the study. In addition, the patients 
were informed that they could withdraw from the study 
at any time, without any prior notice and without any 
consequences. They would still be able to receive all 
other forms of appropriate treatments from the hospital 
without any bias or prejudice.
RESULTS
A total of 60 patients were included in the study, of which 
45% were male. The average age of the sample population 
was 47.6 ± 9.6 (range 30–65) years. The average body mass 
index (BMI) was 24.9 ± 2.9 kg/m2, with female subjects 
having slightly higher BMIs than the male subjects (25.8 
± 3.0 kg/m2). The placebo group consisted of 27 patients 
and the methylcoblamin group, 33 patients. There was no 
significant difference between the two groups in terms of 
gender, age, BMI, ODI scores and VAS scores (p > 0.05), 
which indicates that the sample population from the two 
groups was homogenous. 
 At two months, 58 patients were available for 
review, with 26 from the placebo group and 32 from 
the methylcobalamin group. Two patients voluntarily 
withdrew from the study (one patient each from the 
placebo and treatment groups) due to adverse reactions 
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(pain and haematoma) and lack of improvement in the 
symptoms.
 No significant reduction in ODI scores was 
observed in the placebo group (p > 0.05) after two 
months. However, we found a significant reduction in 
ODI scores in the methylcobalamin group (p < 0.05), 
from 64.0 ± 18.3 to 47.0 ± 22.3, with a mean difference 
of 17.0 (Table I & Fig. 1). Similarly, no significant 
reduction in VAS scores was noted in the placebo group 
(p > 0.05) after two months, but we found a significant 
reduction in VAS scores in the methylcobalamin 
group (p < 0.05), from 56.0 ± 18.6 to 38.6 ± 22.3, with 
a mean difference of 17.4. (Table II & Fig. 2). The 
consumption of  paracetamol was significantly lower 
in the methylcobalamin group compared to the placebo 
group (p < 0.05) (Table III and Fig. 3). Approximately 
40% of the patients encountered minor adverse 
reactions, mainly persistent pain (lasting > 24 hours) 
and haematoma at the injection site (Fig. 4).
DISCUSSION
The results of this study showed that parenteral 
intramuscular injection of methylcobalamin was more 
effective than the placebo in relieving NSLBP and its related 
disability. The value of methylcobalamin in the treatment 
of NSLBP is based on two postulated fundamental modes 
of therapeutic action exhibited by it, namely the analgesic 
and analgesia-potentiating/enhancing properties, as well 
as its neurosynthesis/neuroprotective properties.
 For many years, methylcobalamin and the B12 
group of vitamins had been used to treat pain.  In some 
countries, vitamin B12 is categorised as an analgesic drug. 
Scientists have been searching for the basis for its pain-
relieving and pain-potentiating properties. To this end, 
numerous animal studies have been conducted to date,(4-8) 
and all of these studies have shown favourable results, 
indicating that vitamin B12 does indeed possess analgesic 
characteristics. A few theories concerning the analgesic 
properties of vitamin B12 have been postulated. One such 
theory suggested that the analgesic effect of vitamin 
B12 is the result of its inhibition of synthesis and action 
of inflammatory mediators.(7) Another theory attributed 
the analgesic effect of vitamin B12 to an increased 
availability and effectiveness of noradrenaline and 
5-hydroxytryptamine acting as inhibitory transmitters in 
the nociceptive system.(21)
 Vitamin B12 is often used in combination with 
other analgesics, especially NSAIDs. When used in 
combination, it can potentiate the painkilling effect 
of NSAIDs, and thus, reduce the dose and shorten the 
duration needed to achieve the similar analgesic effects of 
NSAIDs alone. In experimental animal studies conducted 
on rats, the analgesic properties of vitamin B12 were found 
to have a synergistic effect with NSAIDs.(10-13) Several 
Fig. 1 Graph shows the mean Oswestry Disability Index scores 
at baseline and post treatment.
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Fig. 2 Graph shows the mean Visual Analogue Scale pain scores 
at baseline and post treatment.
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Table I. Mean Oswestry Disability Index (ODI) scores at 
baseline and post treatment. 
Group Mean ODI ± SD p-value*
Baseline  
(0 mth)
Post treatment 
(2 mth)
Placebo 60.5 ± 15.4 55.3 ± 20.5 0.102
Methylcobalamin 64.0 ± 18.3 47.0 ± 22.3 < 0.001
* Wilcoxon signed-ranks test. SD: standard deviation
Table II. Mean Visual Analogue Scale (VAS) pain scores 
at baseline and post treatment. 
Group Mean VAS ± SD p-value*
Baseline  
(0 mth)
Post treatment 
(2 mth)
Placebo 54.8 ± 16.1 51.5 ± 19.4 0.420
Methylcobalamin 56.0 ± 18.6 38.6 ± 22.3 < 0.001
* Paired t-test. SD: standard deviation
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clinical studies examining this analgesia-potentiating 
property of vitamin B12 have found that it has a positive 
influence in alleviating pain by reducing NSAID dosages 
and its duration in patients with back pain.(14-16)
 Moreover, evidence-based studies have shown 
that methylcobalamin improves neuropathic pain.(17-19) 
Peripheral neuropathy, a known complication in patients 
with diabetes mellitus, frequently causes neuropathic 
and somatic pain in these patients, which may be due to 
degradation of the peripheral nerves caused by the disease. 
Methylcobalamin has been found to improve neuropathic 
and somatic pain in diabetics, possibly through its neuro-
synthesis and neuro-protective actions.(17,18) Waikakul et 
al found that methylcobalamin improved the neurologic 
claudication distance in patients with lumbar spinal 
stenosis in a clinical trial done in 153 patients with a two-
year follow-up period.(20)
 The question of how the principal function of 
methylcobalamin is linked to the treatment success of 
NSLBP has yet to be answered. Even with the distinction 
in LBP classification into specific and nonspecific, the 
natural progression of nerve root pain from a non-serious 
spinal disorder may not present with a specific clinical 
finding initially. In lumbar disc disease, it has been shown 
that most patients who were hospitalised for sciatica would 
have suffered their first episode of LBP while in their third 
decade of life, with an approximate mean interval of ten 
years.(28) Weber attributed this long interval between the 
onset of LBP and the onset of radicular pain to intradiscal 
degeneration and regeneration forces.(28)  The considerable 
overlap between nerve root compression pain and NSLBP 
occurs due to the undetectable clinical and radiographic 
features early in the disease process. A retrospective 
review of 1,293 patients with a diagnosis of NSLBP 
over a 12-year period revealed that almost 30% had an 
identifiable nerve root compression lesion.(29) This points 
to the proposition that early nerve root irritation may fall 
under the diagnosis of NSLBP, which may be effectively 
treated with intramuscular methylcobalamin.
 Conservative management is still the mainstay of 
treatment recommended by practitioners for mild to 
moderate nerve root compression disease.(30,31) Prospective 
studies have shown that there was no significant 
difference in the long-term outcome between surgical 
and nonsurgical treatment in patients with nerve root 
compression due to lumbar disc herniation.(28,32,33) Surgery 
is usually reserved for those with severe or progressive 
neurological symptoms and for those with intractable 
pain. In most instances, a multimodal treatment approach, 
which consists of physical therapy, physical modalities, 
education and pharmacotherapy, is used. Therefore, we 
recommend that intramuscular methylcobalamin could be 
an option in addition to the multimodal treatment of early 
sciatica.
 The full potency of methylcobalamin in relieving 
pain and potentiating/enhancing analgesia is based 
on its ability to deliver high doses of the vitamin into 
the serum. Therefore, a parenteral route was selected 
over oral medication in order to achieve this effect. 
Intramuscular administration is preferred to intravenous 
administration, as it is less invasive but as efficacious as the 
Table III. Paracetamol consumption in the placebo and 
methylcobalamin groups. 
Group Mean paracetamol ± SD (g) p-value*
Placebo 87.6 ± 57.3
0.04
Methylcobalamin 65.7 ± 75.2
* Mann-Whitney test. SD: standard deviation
Fig. 3 Graph shows the consumption of paracetamol in the 
placebo and metylcobalamin groups.
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Fig. 4 Graph shows the adverse reactions in the placebo and 
methylcobalamin groups.
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intravenous route. Studies have shown that intramuscular 
administration of methylcobalamin produces rapid and 
higher therapeutic serum levels in humans.(25,26) Both 
the placebo and methylcobalamin exhibited only minor 
adverse reactions, as shown in Fig. 4. These adverse 
reactions resolved spontaneously without any active 
treatment. No serious adverse events were recorded 
throughout the study. Thus, we found that intramuscular 
methylcobalamin is safe for use in the treatment of 
patients with NSLBP.
 Intramuscular methylcobalamin may prove to be 
a useful additional treatment for NSLBP, which may 
include a wide variety of disorders, such as chronic 
non-neurological intervertebral disorders, degenerative 
disorders of the spine and musculoskeletal problems of the 
lower back. However, due to the limitations of this study, 
only short-term benefits were recorded, and thus, the long-
term effects of intramuscular methylcobalamin remain 
unknown. Further studies to examine the long-term 
benefits of intramuscular methylcobalamin are required.
 In conclusion, intramuscular methylcobalamin is 
both effective and safe when used to treat patients with 
NSLBP. Our patients experienced significantly less pain 
after two months of treatment, required significantly 
less analgesics, and had improvements in their disability 
scores. Only mild adverse reactions were observed in 
some patients. Therefore, intramuscular methylcobalamin 
is an efficacious medication, used either in isolation or as 
an adjunct to other forms of treatment, for patients with 
NSLBP.
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